Feed OGEN
OG

Oragenics, Inc.

OGEN · AMEX

$0.49 -3.34% (-$0.02)
1M -9.83%
Market Cap $2.27M
P/E Ratio -
Div. Yield -
ROE 144.23%

Bulios Fair Price

$0.71

45.9% upside

Preț actual

$0.49

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile OGEN sunt în prezent subevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Weak
1/9
Valuation
100 /100
Cheap
P/B 0.62x
P/FCF N/A
P/S N/A
Growth
0 /100
Declining
Book val. growth 13.98%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor
Asset turnover 0.00x
ROA 183.59%
ROIC 279.54%
Debt
69 /100
Low
Current ratio 3.01x
Int. coverage -551.49x
Debt/Equity 0.00x
Stability
21 /100
Unstable
EPS volatility 134.39%
Profitable years 0
Beta 1.25x

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre OGEN
Online

Despre companie

Oragenics Inc. (OGEN) is a biotechnology company focused on the development and commercialization of therapeutic and diagnostic products in the field of medical microbiomics. With a product portfolio including drugs and diagnostic tests targeting the treatment of infectious diseases and improvement of microbiome health, Oragenics plays a key role in research and development of new therapeutic and diagnostic approaches. The company focuses on utilizing knowledge of the microbiome to discover new therapeutic targets and diagnostic markers, which may lead to the development of more effective drugs and diagnostic tools. With growing awareness of the importance of the microbiome for human health and the need for innovative therapeutic methods and diagnostic tests, Oragenics has the potential for further growth and development. OGEN shares could be suitable for investors seeking exposure in the biotechnology sector with a focus on microbiome and innovative therapeutic and diagnostic approaches.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Janet Huffman

Employees

3

Headquarters

Lakewood Ranch

Evenimente viitoare

16 NOV.

Earnings

Upcoming earnings report

65d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.